Amazon, Berkshire, JPMorgan name Atul Gawande CEO of healthcare venture

Share

Amazon, JPMorgan Chase and Berkshire Hathaway have picked well-known author and surgeon Dr. Atul Gawande to head their health-care venture, aimed at transforming the health care they give their employees.

"I'm thrilled to be named CEO of this healthcare initiative", said Atul Gawande, a Brigham & Women's doctor and the CEO of the new company, in a statement. I have devoted my public health career to building scalable solutions for better healthcare delivery that are saving lives, reducing suffering, and eliminating wasteful spending both in the USA and across the world.

"I have devoted my public health career to building scalable solutions for better healthcare delivery that are saving lives, reducing suffering, and eliminating wasteful spending both in the U.S. and across the world", Gawande said in a statement from the group announcing his appointment. "And, you know, if you had some really smart people running it that knew a lot about medicine, they're going to-they could do a lot about it", Buffett said in the appearance.

The surgeon and New Yorker writer was named CEO of the yet-to-be named company that aims to fix problems in health care for United States workers. He is also well known for his books and writing in the New Yorker about the US health-care system.

Munger thought the article was so socially useful that he blindly mailed Gawande a $20,000 check, Buffett told CNBC at the time.

More news: John Travolta Reportedly Believed Gotti Would Be An Awards Contender
More news: WHO classifies video game addiction as a mental health disorder
More news: Duke alum Stephen Miller 'instrumental' in Trump's policy to separate migrant families

Amazon and its partners say they will use big-data analysis and other high-tech tools to improve care and cut wasteful spending.

JPMorgan CEO Jamie Dimon has said he wants the joint venture to deal with the "extraordinary" spending on end-of-life care when such interventions may not help.

The consortium's leaders have said they aren't looking for a quick fix. The move rattled shares of the healthcare supply chain, including CVS Health and Express Scripts, among others.

Publicly, though, the three have lamented a system where rampant price increases have left the nation with an increasingly heavy financial burden, and it's a discussion which biopharma companies have a direct interest in. And he's one of the best-known figures in the industry.

Share